Renal cell carcinoma and interleukin-2: what are the endpoints?

Editorial

R A Figlin. Cancer J Sci Am. 1997 Dec.

. 1997 Dec:3 Suppl 1:S68-9.

No abstract available

Comment on

High-dose aldesleukin in renal cell carcinoma: long-term survival update.
Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G. Fisher RI, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S70-2. Cancer J Sci Am. 1997. PMID: 9457398 Clinical Trial.
An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
Yang JC, Rosenberg SA. Yang JC, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S79-84. Cancer J Sci Am. 1997. PMID: 9457400 Clinical Trial.
Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2.
Gold PJ, Thompson JA, Markowitz DR, Neumann S, Fefer A. Gold PJ, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S85-91. Cancer J Sci Am. 1997. PMID: 9457401 Clinical Trial.
Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R, Gitlitz B, Franklin J, Dorey F, Moldawer N, Rausch J, deKernion J, Belldegrun A. Figlin R, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S92-7. Cancer J Sci Am. 1997. PMID: 9457402 Clinical Trial.
Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience.
Huland E, Heinzer H, Mir TS, Huland H. Huland E, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S98-105. Cancer J Sci Am. 1997. PMID: 9457403 Clinical Trial.